Dr Nikola Bowden

Dr Nikola Bowden

Research Fellow

School of Medicine and Public Health (Medical Genetics)

Unlocking the mysteries of Melanoma

Dr Nikola Bowden, recipient of the 2015 Young Tall Poppy Science Award, is investigating DNA repair to unlock the mysteries of melanoma and provide new hope for patients world-wide.

Nikola BowdenAs a molecular biologist at University of Newcastle, Dr Nikola Bowden appreciates the importance of scientific process, but as a researcher she has also learnt the value of trusting her instincts. It was a gut feeling that prompted Bowden to pursue a line of research that has consequently shifted the central dogma around the role of DNA repair in melanoma development and provided a possible explanation for why the disease is largely resistant to chemotherapy.

Bowden's breakthrough paper on nucleotide expression repair in melanoma, published in the journal Cancer Research in 2010, was the first to report on the relationship between DNA repair pathways and chemotherapy resistance in melanoma.

"Chemotherapy usually works by attacking the DNA of a cancer cell and damaging it so badly that it dies. Normally, the DNA repair pathway in a cell will either fix the damage, as it does when we get sunburnt, or 'tell' a cell to die when the damage is extreme. But in melanoma this pathway is dysfunctional, so chemotherapy has little or no effect and the cancerous cells continue to accumulate damage and grow."

Because the same DNA repair pathway fixes damage to cells from sunlight, Bowden is now pursuing the hypothesis that dysfunction in the pathway could increase susceptibility to melanoma.

"I was surprised to find that no one had pursued this line of research before – it is almost as if it had been dismissed because it was too obvious," Bowden remarks.

After the initial research phase, Bowden turned to patients for feedback and it was at this point that her research project took another turn.

"We presented our findings to a patient consultation group, who asserted that we should now focus on using the research to improve treatment, and so we did. We've used the initial research on DNA repair to successfully prove that certain drugs could be used to switch the patient's DNA repair back on and hopefully trigger the immune system to help fight the cancerous cells."

The initial findings in Bowden's research are promising and the project is beginning to attract the attention of pharmaceutical companies.

"We found that using a combination of drugs in a staged approach would have the least impact on the patient. We are using the same drugs that have been around for 30-40 years, we are simply using them for a new purpose and the results are looking positive."

To ensure the drugs are suitable for clinical trials, Bowden collaborates with Dr Andre van der Westhuizen, a melanoma oncologist who also happens to be based in the Hunter.

"I met Dr van der Westhuizen at the International Melanoma Congress in Philadelphia. On our return to Australia, he started meeting with us fortnightly. His feedback has helped shape the research and he will now run clinical trials for a small number of people who have no alternative treatments."

If successful, the treatment will offer new hope to melanoma patients world-wide providing a more effective and affordable solution. With 132,000 new cases of melanoma diagnosed each year, Bowden and her team could revolutionise the treatment of melanoma around the world.

Bowden's research project is supported by the Cancer Institute NSW  Cure Cancer Australia Foundation and the Hunter Medical Research Institute (HMRI).

Find out more

Global leaders driving world class innovation

Nikola Bowden in the laboratory

Unlocking the mysteries of Melanoma

Dr Nikola Bowden uses next-generation genetic profiling techniques to unlock the mysteries of melanoma.

Read more

Career Summary

Biography

Dr Nikola Bowden was appointed at the University of Newcastle in 2006 as the inaugural NBN Telethon childhood cancer post-doctoral fellow. Subsequent to this in 2008 she was awarded a Gladys M. Brawn memorial post-doctoral fellowship from the Faculty of Health, University of Newcastle. In January 2009 Dr Bowden was appointed as a Lecturer in the School of Biomedical Sciences & Pharmacy and was awarded an NH&MRC training (post-doctoral) fellowship which she commenced in October 2009. Since 2006, Dr Bowden has developed a research interest with the overall aim of delivering personalised diagnosis and treatment to patients with cancer, with a more focused interest in investigating DNA repair in melanoma. Dr Bowden's research has been funded through a nationally competitive fellowship and grants from the NH&MRC, Cure Cancer Australia Foundation and Cancer Australia, respectively. Dr Bowden collaborates with Dr Daniel Catchpoole at the Children’s Hospital at Westmead and has international collaborations with Prof James Cleaver from University of California San Francisco (USA) and Dr Javed Khan from the National Cancer Institute and National Institutes of Health (USA). Dr Bowden has obtained over $1,000,000 in funding, published 22 articles in international peer-reviewed journals and have presented her research over 60 times at international and national conferences. Dr Bowden currently supervises 4 research higher degree PhD students. Dr Bowden was awarded the University of Newcastle Young Alumni Award in 2011 and was part of a collaboration awarded the Schizophrenia Research Institute Research Paper Award in 2008 and was the recipient of the 2007 Hunter Children's Research Foundation (HCRF) Award for Research Excellence for her research into the DNA repair and skin cancer disorder, Xeroderma Pigmentosum, and childhood acute lymphoblastic leukaemia. In 2006, she was awarded the Hunter Medical Research Institute (HMRI) PULSE Education Prize, an award presented to an outstanding early career researcher. Dr Bowden has been an invited reviewer for the international funding body Medical Research Council (UK), and many international journals.

Research Expertise
Below is a summary of my current research projects: Nucleotide Excision Repair Gene Expression in Melanoma: My main research program is investigating the role of DNA repair in cancer. The results of a pilot study into deficient DNA repair in melanoma have been published in the journal Cancer Research. The publication of this manuscript represents a shift in the central dogma surrounding DNA repair and melanoma. To date there has been a central belief that DNA repair is not involved in development of melanoma. The results of our study have now confirmed the hypothesis that a deficiency in DNA repair is indeed a feature of melanoma and may be the reason why melanomas develop after excessive sun exposure and why melanomas do not respond to common chemotherapeutic agents. The major outcome of this research program will be a biological explanation for why excessive sunlight exposure results in melanomagenesis and why melanomas do not respond to common DNA-damaging chemotherapeutic agents, two of the most elusive features of melanoma. In addition, I collaborate with Dr Ricardo Vilain and Dr Stephen Braye from the Hunter Area Pathology Service (HAPS) Anatomocal Pathology department to utilise formalin-fixed paraffin embedded (FFPE) melanoma tissue collected and stored for diagnostic purposes. This tissue represents a very large cohort of individuals from the hunter region with melanoma and allows for retrospective analysis of clinical data such as disease recurrence, response to treatment and survival. Another major advantage of using this tissue is that it requires no direct participation from patients with melanoma thus lessening the burden of research on clinicians and patients. This collaboration was established in 2009 and the preliminary results of several projects have been presented at the 7th and 8th International Congress of the Society for Melanoma Research (2010 & 2011).

Teaching Expertise
The following is a summary of my major research training and teaching: • Currently primary supervisor of 4 PhD students, co-supervisor of 3 PhD students. Previously supervised 3 !st Class Honours students. • Supervised B. Biomedical Science 3rd year HUBS3409 students to undertake research project (2009 & 2011) • Delivered the lectures and tutorials for the genetics and genomics component of the M. Pharmacy course PHAR6123 – Human Genomics and Biomolecular Analysis (2005, 2006, 2008, 2011, 2013) • Delivered 6 lectures for B. Biomedical Science HUBS2409 Bioinformatics and Functional Genomics in 2008 and annual guest lectures in 2005-2006. 

Qualifications

  • PhD, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Chemotherapy
  • DNA repair
  • Genetics
  • Melanoma
  • UV-light

Fields of Research

Code Description Percentage
060199 Biochemistry and Cell Biology not elsewhere classified 50
111299 Oncology and Carcinogenesis not elsewhere classified 50

Professional Experience

UON Appointment

Title Organisation / Department
Research Fellow University of Newcastle
School of Medicine and Public Health
Australia
Research Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

Dates Title Organisation / Department
1/01/2015 -  Cancer Institute NSW Career Development Fellow University of Newcastle - Faculty of Health and Medicine
1/10/2009 - 31/12/2014 NHMRC Early Career Fellow University of Newcastle - Faculty of Health and Medicine
1/09/2009 - 1/12/2014 Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2009 - 1/10/2009 Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2008 - 1/12/2008 Postdoctoral Fellow - Gladys M. Brawn Memorial University of Newcastle
Australia
1/01/2006 - 1/12/2007 NBN Telethon Postdoctoral Fellow University of Newcastle
Hunter Medical Research Institute
Australia

Membership

Dates Title Organisation / Department
1/01/2012 -  Membership - NHMRC Post-Doctoral Reference Group The NHMRC Postdoctoral Reference Group
Australia
1/01/2012 -  Membership - NHMRC Research Translation Faculty NHMRC Research Translation Faculty
Australia
1/01/2010 -  Membership - Society for Melanoma Research Society for Melanoma Research
Australia
1/01/2008 -  Membership - American Association of Cancer Research American Association of Cancer Research
United States
1/01/2006 -  Membership - Australian Society of Medical Research Australian Society of Medical Research
Australia

Professional appointment

Dates Title Organisation / Department
1/06/2015 -  Women in Science AUSTRALIA Executive committee Women in Science AUSTRALIA
Australia
1/01/2014 -  Early-Mid Career Researcher Forum Committee Member Australian Academy of Sciences
Australia

Awards

Recipient

Year Award
2011 Young Alumni Award
University of Newcastle

Recognition

Year Award
2012 Emerging Research Leaders Program
University of Newcastle
2007 INSIGHT
Hunter Medical Research Institute

Research Award

Year Award
2007 Award for Research Excellence
Hunter Medical Research Institute (HMRI)
2006 PULSE Education Prize
Hunter Medical Research Institute
2006 Student Support Award to attend the International Congress on
Human Genetics Society of Australasia (HGSA)
2004 Student Travel Award
International Society of Psychiatric Genetics
2003 Student Travel Award
Australasian Neuroscience Society
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (36 outputs)

Year Citation Altmetrics Link
2016 Bolton KA, Avery-Kiejda KA, Holliday EG, Attia J, Bowden NA, Scott RJ, 'A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer.', Endocr Connect, 5 115-122 (2016) [C1]
DOI 10.1530/EC-16-0003
Co-authors John Attia, Kelly Kiejda, Liz Holliday
2016 Day T, Bowden N, Jaaback K, Otton G, Scurry J, 'Distinguishing erosive lichen planus from differentiated vulvar intraepithelial neoplasia', Journal of Lower Genital Tract Disease, 20 174-179 (2016) [C1]

© 2016, American Society for Colposcopy and Cervical Pathology.Erosive lichen planus and differentiated vulvar intraepithelial neoplasia may closely resemble each other histologi... [more]

© 2016, American Society for Colposcopy and Cervical Pathology.Erosive lichen planus and differentiated vulvar intraepithelial neoplasia may closely resemble each other histologically and require clinicopathological correlation to be distinguished. Objective Erosive lichen planus (LP) and differentiated vulvar intraepithelial neoplasia (dVIN) may display overlapping histopathologic features. Materials and Methods We searched the local pathology database for vulvar biopsies reported as dVIN or erosive vulvitis during 2011 to 2013 inclusive. After review of patient notes and slides, there were 5 cases with a clinical appearance and course consistent with erosive LP and histopathology showing epithelial regeneration. We then selected 5 cases of dVIN in which the clinical course and histopathology supported the diagnosis. We performed immunohistochemistry for p16 and p53 on all cases and did copy variant analysis on 1 case each of erosive LP and dVIN. Results Histopathology of the LP cases showed epithelial thinning, absent stratum corneum, lack of maturation, as well as nuclear changes of enlargement, pleomorphism, and hyperchromasia. Three LP cases (60%) showed a wild-type p53 pattern and 2 (40%) were confluent positive. Two dVIN cases (40%) showed full-thickness loss of differentiation. One case (20%) of dVIN was p53 negative, 2 (40%) were wild-type, 1 was confluent positive, and 1 showed dark suprabasilar staining. All cases were negative for p16. Compared with control, erosive LP epithelium showed a similar copy-number pattern, whereas the dVIN epithelium had many copy-number changes. Conclusions A small subset of clinically diagnosed vulvovaginal erosive LP will show on histopathology a regenerative erosive vulvitis with loss of epithelial maturation and nuclear changes, which requires clinicopathologic correlation to distinguish from dVIN.

DOI 10.1097/LGT.0000000000000179
2016 Murray HC, Maltby VE, Smith DW, Bowden NA, 'Nucleotide excision repair deficiency in melanoma in response to UVA', Experimental Hematology and Oncology, 5 (2016) [C1]

© 2016 Murray et al.Background: The causative link between UV exposure and melanoma development is well known, however the mechanistic relationship remains incompletely character... [more]

© 2016 Murray et al.Background: The causative link between UV exposure and melanoma development is well known, however the mechanistic relationship remains incompletely characterised. UVA and UVB components of sunlight are implicated in melanomagenesis; however the majority of studies have focused on the effects of UVB and UVC light. Interestingly, melanoma tumour sequencing has revealed an overrepresentation of mutations signature of unrepaired UV-induced DNA damage. Repair of UVA-induced DNA damage is thought to occur primarily through the Nucleotide Excision Repair (NER) pathway, which recognises and repairs damage either coupled to transcription (Transcription Coupled Repair; TCR), or through global genome scanning (Global Genome Repair; GGR). Current literature suggests NER is deficient in melanoma, however the cause of this remains unknown; and whether reduced NER activity in response to UVA may be involved in melanoma development remains uncharacterised. In this study we aimed to determine if melanoma cells exhibit reduced levels of NER activity in response to UVA. Methods: Melanocyte and melanoma cell lines were UVA-irradiated, and DNA damage levels assessed by immunodetection of Cyclobutane Pyrimidine Dimer (CPD) and (6-4) Photoproduct [(6-4)PP] lesions. Expression of NER pathway components and p53 following UVA treatment was quantified by qPCR and western blot. Results: UVA did not induce detectable induction of (6-4)PP lesions, consistent with previous studies. Repair of CPDs induced by UVA was initiated at 4 h and complete within 48 h in normal melanocytes, whereas repair initiation was delayed to 24 h and >40 % of lesions remained in melanoma cell lines at 48 h. This was coupled with a delayed and reduced induction of GGR component XPC in melanoma cells, independent of p53. Conclusion: These findings support that NER activity is reduced in melanoma cells due to deficient GGR. Further investigation into the role of NER in UVA-induced melanomagenesis is warranted and may have implications for melanoma treatment.

DOI 10.1186/s40164-016-0035-4
Co-authors Vicki E Maltby, Douglas Smith
2016 Bowden NA, Smyth M, Jaaback K, Ashton KA, Scurry J, 'Genetic changes correlate with histopathology in a benign, borderline and malignant mucinous ovarian tumour', Journal of Obstetrics and Gynaecology, 36 119-121 (2016) [C3]
DOI 10.3109/01443615.2015.1036406
Co-authors Katie Ashton
2016 Bolton KA, Holliday EG, Attia J, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer', BMC Research Notes, 9 (2016)

© 2016 The Author(s).Background: The estrogen-induced gene 121 (EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a... [more]

© 2016 The Author(s).Background: The estrogen-induced gene 121 (EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search for tandem repeats, we found that EIG121 contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expression. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk. Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically significant association was identified between the length of this STR and the risk of developing breast or endometrial cancer or age at diagnosis. Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its association with disease recurrence or overall survival remains to be determined.

DOI 10.1186/s13104-016-2086-3
Co-authors John Attia, Kelly Kiejda, Liz Holliday, Rodney Scott
2016 Davey RJ, Westhuizen AVD, Bowden NA, 'Metastatic melanoma treatment: Combining old and new therapies', Critical Reviews in Oncology/Hematology, 98 242-253 (2016)

© 2015 Elsevier Ireland Ltd.Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for meta... [more]

© 2015 Elsevier Ireland Ltd.Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for metastatic melanoma were very limited. Largely ineffective dacarbazine, temozolamide or fotemustine were the only agents in use for 35 years. In recent years, the development of molecularly targeted inhibitors in parallel with the development of checkpoint inhibition immunotherapies has rapidly improved the outcomes for metastatic melanoma patients. Despite these new therapies showing initial promise; resistance and poor duration of response have limited their effectiveness as monotherapies. Here we provide an overview of the history of melanoma treatment, as well as the current treatments in development. We also discuss the future of melanoma treatment as we go beyond monotherapies to a combinatorial approach. Combining older therapies with the new molecular and immunotherapies will be the most promising way forward for treatment of metastatic melanoma.

DOI 10.1016/j.critrevonc.2015.11.011
Citations Scopus - 2Web of Science - 2
2015 Ashton KA, Scurry J, Tabrizi SN, Garland SM, Otton G, Bowden NA, 'The problem of late ovarian metastases from primary cervical adenocarcinoma.', Gynecologic oncology reports, 13 23-25 (2015) [C3]
Co-authors Katie Ashton
2015 Bowden NA, Beveridge NJ, Ashton KA, Baines KJ, Scott RJ, 'Understanding xeroderma pigmentosum complementation groups using gene expression profiling after UV-light exposure', International Journal of Molecular Sciences, 16 15985-15996 (2015) [C1]

© 2015 by the authors; licensee MDPI, Basel, Switzerland.Children with the recessive genetic disorder Xeroderma Pigmentosum (XP) have extreme sensitivity to UV-light, a 10,000-fo... [more]

© 2015 by the authors; licensee MDPI, Basel, Switzerland.Children with the recessive genetic disorder Xeroderma Pigmentosum (XP) have extreme sensitivity to UV-light, a 10,000-fold increase in skin cancers from age 2 and rarely live beyond 30 years. There are seven genetic subgroups of XP, which are all resultant of pathogenic mutations in genes in the nucleotide excision repair (NER) pathway and a XP variant resultant of a mutation in translesion synthesis, POLH. The clinical symptoms and severity of the disease is varied across the subgroups, which does not correlate with the functional position of the affected protein in the NER pathway. The aim of this study was to further understand the biology of XP subgroups, particularly those that manifest with neurological symptoms. Whole genome gene expression profiling of fibroblasts from each XP complementation group was assessed before and after UV-light exposure. The biological pathways with altered gene expression after UV-light exposure were distinct for each subtype and contained oncogenic related functions such as perturbation of cell cycle, apoptosis, proliferation and differentiation. Patients from the subgroups XP-B and XP-F were the only subgroups to have transcripts associated with neuronal activity altered after UV-light exposure. This study will assist in furthering our understanding of the different subtypes of XP which will lead to better diagnosis, treatment and management of the disease.

DOI 10.3390/ijms160715985
Citations Scopus - 1Web of Science - 1
Co-authors Rodney Scott, Katie Ashton, Katherine Baines
2014 Evans TJ, Milne E, Anderson D, de Klerk NH, Jamieson SE, Talseth-Palmer BA, et al., 'Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.', PLoS One, 9 e110255 (2014) [C1]
DOI 10.1371/journal.pone.0110255
Citations Scopus - 4Web of Science - 4
Co-authors Liz Holliday, Bente Talseth-Palmer, Rodney Scott, John Attia
2014 Ashton KA, Scurry J, Ouveysi A, Ebbs J, Jaaback K, Bowden NA, 'Transformation of endometrioid carcinoma to carcinoma with trophoblastic differentiation: clinicopathological and whole genomic study.', Pathology, 46 351-353 (2014) [C3]
DOI 10.1097/PAT.0000000000000101
Co-authors Katie Ashton
2014 Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', International Journal of Cancer, 134 301-305 (2014) [C1]

Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor ... [more]

Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor negativity. TNBCs share a similar gene expression profile to BRCA-mutated tumours, have been shown to carry a high proportion of BRCA mutations and have a more adverse prognosis compared to other types of breast tumours. PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. In our study, we sequenced the coding regions of PALB2 (including intron/exon boundaries) in genomic DNA from 347 patients diagnosed with TNBC to determine the prevalence of deleterious mutations in this population. Two novel truncating mutations (c.758dup and c.2390del) and one previously detected truncating mutation (c.3113+5G>C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts. © 2013 UICC.

DOI 10.1002/ijc.28361
Citations Scopus - 4Web of Science - 3
Co-authors Kelly Kiejda, Michelle Wong-Brown, Rodney Scott
2014 Bowden NA, 'Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?', Cancer Letters, (2014) [C1]

Platinum based therapy is one of the most effectively used chemotherapeutic treatments for cancer. The mechanism of action of platinum compounds is to damage DNA and drive cells i... [more]

Platinum based therapy is one of the most effectively used chemotherapeutic treatments for cancer. The mechanism of action of platinum compounds is to damage DNA and drive cells into apoptosis. The most commonly used platinum containing agents are cis-diammine-dichloroplatinum (II)], more commonly known as cisplatin, its analogue carboplatin, and oxaliplatin. Cisplatin is used to treat a wide variety of tumours such as ovarian, testicular, head and neck and non-small cell lung cancers (NSCLCs). In addition, it forms the basis of most combined treatment regimes. Despite this, cisplatin and its analogues are extremely toxic and although some patients benefit substantially from treatment, a large proportion suffer the toxic side effects without any therapeutic benefit. Nucleotide excision repair (NER) is a versatile DNA repair system that recognises DNA damage induced by platinum based therapy. For many years the components of the NER pathway have been studied to determine mRNA and protein expression levels in response or resistance to cisplatin in many forms of cancer; particularly testicular, ovarian and NSCLCs. Despite the consistent finding that over or under expression of subsets of NER proteins and mRNA highly correlate with response to cisplatin, the translation of these findings into the clinical setting has not been forthcoming. This review summarises the results of previous investigations into NER in cisplatin response and clinical trials where the expression of NER proteins were compared to the response to platinum therapies in treatment. © 2014 Elsevier Ireland Ltd. All rights reserved.

DOI 10.1016/j.canlet.2014.01.005
Citations Scopus - 32Web of Science - 25
2014 Wan C, Latter JL, Amirshahi A, Symonds I, Finnie J, Bowden N, et al., 'Progesterone Activates Multiple Innate Immune Pathways in Chlamydia trachomatis-Infected Endocervical Cells', American Journal of Reproductive Immunology, 71 165-177 (2014) [C1]

Problem: Susceptibility to Chlamydia trachomatis infection is increased by oral contraceptives and modulated by sex hormones. We therefore sought to determine the effects of femal... [more]

Problem: Susceptibility to Chlamydia trachomatis infection is increased by oral contraceptives and modulated by sex hormones. We therefore sought to determine the effects of female sex hormones on the innate immune response to C. trachomatis infection. Method of study: ECC-1 endometrial cells, pre-treated with oestradiol or progesterone, were infected with C. trachomatis and the host transcriptome analysed by Illumina Sentrix HumanRef-8 microarray. Primary endocervical epithelial cells, prepared at either the proliferative or secretory phase of the menstrual cycle, were infected with C. trachomatis and cytokine gene expression determined by quantitative RT-PCR analysis. Results: Chlamydia trachomatis yield from progesterone-primed ECC-1 cells was significantly reduced compared with oestradiol-treated cells. Genes upregulated in progesterone-treated and Chlamydia-infected cells only included multiple CC and CXC chemokines, IL-17C, IL-29, IL-32, TNF-a, DEFB4B, LCN2, S100A7-9, ITGAM, NOD2, JAK1, IL-6ST, type I and II interferon receptors, numerous interferon-stimulated genes and STAT6. CXCL10, CXCL11, CX3CL1 and IL-17C, which were also upregulated in infected secretory-stage primary cells, and there was a trend towards higher levels of immune mediators in infected secretory-phase compared with proliferative-phase cells. Conclusion: Progesterone treatment primes multiple innate immune pathways in hormone-responsive epithelial cells that could potentially increase resistance to chlamydial infection. © 2013 John Wiley & Sons Ltd.

DOI 10.1111/aji.12168
Citations Scopus - 4Web of Science - 5
Co-authors Ian Symonds, Rodney Scott, Joanna Latter
2014 Cox MB, Bowden NA, Scott RJ, Lechner-Scott J, 'Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis', Multiple Sclerosis Journal, 20 489-491 (2014) [C1]

Matrix metalloproteinase 9 (MMP9) is involved in multiple sclerosis (MS) aetiology. Previously, we identified differential gene expression of plasminogen activation cascade genes ... [more]

Matrix metalloproteinase 9 (MMP9) is involved in multiple sclerosis (MS) aetiology. Previously, we identified differential gene expression of plasminogen activation cascade genes in MS patients. Based on our gene expression results, we wanted to identify whether polymorphisms in the genes associated with the plasminogen pathway could predict MS risk. We genotyped 1153 trio families, 727 MS cases and 604 healthy controls for 17 polymorphisms in MMP9, plasminogen activator urokinase (PLAU), PLAU receptor (PLAUR) and serpin peptidase inhibitor/clade 2/member B2 (SERPINB2) genes. No associations were found between the 17 polymorphisms and MS. Also, gene expression levels were analysed according to genotype: no associations were observed. In conclusion despite the consistent evidence for the role of MMP9 and the plasminogen activation cascade in MS, we found no associations between genotype nor gene expression. This suggested there are other potentially modifiable factors influencing gene expression in MS. © The Author(s) 2013.

DOI 10.1177/1352458513498127
Citations Scopus - 1Web of Science - 1
Co-authors Rodney Scott
2013 Cox MB, Bowden NA, Scott RJ, Lechner-Scott J, 'Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation', Multiple Sclerosis Journal, 19 1268-1274 (2013) [C1]
DOI 10.1177/1352458513475493
Citations Scopus - 2Web of Science - 1
Co-authors Rodney Scott
2013 Budden T, Bowden NA, 'The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 14 1132-1151 (2013) [C1]
DOI 10.3390/ijms14011132
Citations Scopus - 23Web of Science - 25
2013 Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'STaRRRT: a table of short tandem repeats in regulatory regions of the human genome', BMC GENOMICS, 14 (2013) [C1]
DOI 10.1186/1471-2164-14-795
Citations Scopus - 8Web of Science - 7
Co-authors Liz Holliday, Kelly Kiejda, Rodney Scott
2013 Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
DOI 10.1371/journal.pone.0070424
Citations Scopus - 1Web of Science - 1
Co-authors Kelly Kiejda, Rodney Scott, Xu Zhang, Katie Ashton
2012 Ashton KA, Scurry JP, Rutherford J, Otton GR, Scott R, Bowden NA, 'Nodular prurigo of the vulva', Pathology, 44 565-567 (2012) [C3]
Citations Scopus - 3Web of Science - 2
Co-authors Katie Ashton, Rodney Scott
2012 Young KMN, Scurry JP, Jaaback KS, Bowden NA, Scott R, 'Bilateral dysgerminoma associated with gonadoblastoma and sex-cord stromal tumour with annular tubules in a 28-year-old fertile woman with normal karyotype', Pathology, 44 257-260 (2012) [C3]
Citations Scopus - 3Web of Science - 2
Co-authors Rodney Scott
2012 Cox MB, Ban M, Bowden NA, Baker A, Scott R, Lechner-Scott J, 'Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis', Multiple Sclerosis Journal, 18 16-22 (2012) [C1]
Citations Scopus - 25Web of Science - 21
Co-authors Rodney Scott
2011 Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
DOI 10.1186/1471-2407-11-203
Citations Scopus - 39Web of Science - 29
Co-authors Xu Zhang, Rodney Scott, Kelly Kiejda, Bente Talseth-Palmer, Katie Ashton
2011 Wong-Brown M, Nordfors C, Mossman D, Pecenpetelovska G, Kiejda KA, Talseth-Palmer B, et al., 'BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer', Breast Cancer Research and Treatment, 127 853-859 (2011) [C1]
DOI 10.1007/s10549-011-1443-0
Citations Scopus - 58Web of Science - 50
Co-authors Rodney Scott, Kelly Kiejda, Bente Talseth-Palmer, Michelle Wong-Brown
2010 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
Citations Scopus - 10Web of Science - 10
Co-authors Xu Zhang, Kelly Kiejda, Rodney Scott, Katie Ashton
2010 Li J, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG, et al., 'IL-27/IFN-y induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages', Journal of Immunology, 185 4401-4409 (2010) [C1]
DOI 10.4049/jimmunol.1001039
Citations Scopus - 47Web of Science - 42
Co-authors Peter Gibson, Philip Hansbro, Ming Yang, Katherine Baines, Paul Foster
2010 Baines KJ, Simpson JL, Bowden NA, Scott R, Gibson PG, 'Differential gene expression and cytokine production from neutrophils in asthma phenotypes', European Respiratory Journal, 35 522-531 (2010) [C1]
DOI 10.1183/09031936.00027409
Citations Scopus - 39Web of Science - 32
Co-authors Katherine Baines, Rodney Scott, Jodie Simpson, Peter Gibson
2009 Talseth-Palmer B, Bowden NA, Meldrum C, Nicholl J, Thompson E, Friend K, et al., 'A 1q44 deletion, paternal UPD of chromosome 2 and a deletion due to a complex translocation detected in children with abnormal phenotypes using new SNP array technology', Cytogenetic and Genome Research, 124 94-101 (2009) [C1]
DOI 10.1159/000200093
Citations Scopus - 5Web of Science - 5
Co-authors Bente Talseth-Palmer, Rodney Scott
2008 Bowden NA, Scott R, Tooney PA, 'Altered gene expression in the superior temporal gyrus in schizophrenia', BMC Genomics, 9 1-12 (2008) [C1]
DOI 10.1186/1471-2164-9-199
Citations Scopus - 32Web of Science - 32
Co-authors Rodney Scott, Paul Tooney
2008 Talseth-Palmer B, Bowden NA, Hill A, Meldrum C, Scott R, 'Whole genome amplification and its impact on CGH array profiles', BMC Research Notes, 1 108 (2008) [C1]
DOI 10.1186/1756-0500-1-56
Citations Scopus - 14
Co-authors Rodney Scott, Bente Talseth-Palmer
2008 Beveridge NJ, Tooney PA, Carroll AP, Gardiner EJ, Bowden NA, Scott R, et al., 'Dysregulation of miRNA 181b in the temporal cortex in schizophrenia', Human Molecular Genetics, 17 1156-1168 (2008) [C1]
DOI 10.1093/hmg/ddn005
Citations Scopus - 186Web of Science - 177
Co-authors Rodney Scott, Murray Cairns, Paul Tooney
2007 Bowden NA, Scott R, Tooney PA, 'Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia', Schizophrenia Research, 89 165-168 (2007) [C1]
DOI 10.1016/j.schres.2006.09.003
Citations Scopus - 36Web of Science - 37
Co-authors Rodney Scott, Paul Tooney
2007 Bowden NA, Croft A, Scott R, 'Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease', Hereditary Cancer in Clinical Practice, 5 79-96 (2007) [C1]
DOI 10.1186/1897-4287-5-2-79
Citations Scopus - 4Web of Science - 4
Co-authors Rodney Scott
2006 Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Altered gene expression in the amygdala in schizophrenia: Up-regulation of genes located in the cytomatrix active zone', Molecular and Cellular Neuroscience, 31 243-250 (2006) [C1]
DOI 10.1016/j.mcn.2005.09.013
Citations Scopus - 36Web of Science - 37
Co-authors Rodney Scott, Judith Weidenhofer, Paul Tooney
2006 Bowden NA, Weidenhofer JC, Scott R, Schall U, Todd J, Michie PT, Tooney PA, 'Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia', Schizophrenia Research, 82 175-183 (2006) [C1]
DOI 10.1016/j.schres.2005.11.012
Citations Scopus - 82Web of Science - 72
Co-authors Judith Weidenhofer, Paul Tooney, Pat Michie, Juanita Todd, Rodney Scott, Ulrich Schall
2006 Bowden NA, Tooney PA, Scott R, 'Gene expression profiling of xeroderma pigmentosum', Hereditary Cancer in Clinical Practice, 4 103-110 (2006) [C1]
DOI 10.1186/1897-4287-4-2-103
Citations Scopus - 2
Co-authors Paul Tooney, Rodney Scott
2006 Weidenhofer J, Bowden NA, Scott RJ, Tooney PA, 'Dysfunction of genes regulating membrane exocytosis in schizophrenia', AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 40 A129-A129 (2006)
Co-authors Rodney Scott, Judith Weidenhofer, Paul Tooney
Show 33 more journal articles

Conference (70 outputs)

Year Citation Altmetrics Link
2014 Warren CFA, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Association of BCL-2B expression with increased survival and response to stress in melanoma suggests a functional role for this previously uncharacterised isoform.', Keystone Symposia on Molecular and Cellular Biology (2014) [E3]
Co-authors Katie Ashton, Pablo Moscato
2014 Bowden NA, 'Overcoming chemoresistance in melanoma and ovarian cancer.', Proceedings of the Inaugural EMBL Australia PhD Symposium (2014) [E3]
2014 Warren CFA, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'A functional role in cellular stress response and melanoma pathology for the previously uncharacterised isoform, Bcl-2B.', Proceedings of the Inaugural EMBL Australia PhD Symposium (2014) [E3]
Co-authors Katie Ashton, Pablo Moscato
2014 Budden T, Davey RJ, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'Repair of UVB-induced DNA damage is reduced in melanoma due to attenuated XPC and global genome repair.', Proceedings of the Inaugural EMBL Australia PhD Symposium (2014) [E3]
Co-authors Rodney Scott, Katie Ashton
2014 Bowden NA, 'How melanoma and melanocytes respond to UV-light and chemotherapy', Skin Cancer College of Australasia (2014) [E3]
2014 Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme (2014) [E3]
Co-authors Rodney Scott, Kelly Kiejda, Liz Holliday
2014 Davey RJ, Budden T, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'REPAIR OF UVB-INDUCED DNA DAMAGE IS REDUCED IN MELANOMA DUE TO ATTENUATED XPC AND GLOBAL GENOME REPAIR', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014)
Co-authors Rodney Scott, Katie Ashton
2014 Budden T, Bowden NA, 'GLOBAL DEMETHYLATION CAN RESTORE XPC EXPRESSION AND OVERCOME PLATINUM THERAPY RESISTANCE IN MELANOMA IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
2014 Davey RJ, Budden T, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'REPAIR OF UVB-INDUCED DNA DAMAGE IS REDUCED IN MELANOMA DUE TO ATTENUATED XPC AND GLOBAL GENOME REPAIR', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Katie Ashton, Rodney Scott
2014 Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'A FUNCTIONAL ROLE IN MELANOMA PATHOLOGY AND CELLULAR RESPONSE TO STRESS FOR THE PREVIOUSLY UNCHARACTERISED ISOFORM, BCL2B', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Katie Ashton, Pablo Moscato
2014 Murray HC, Maltby VE, Bowden NA, 'Nucleotide excision repair in response to UVA is deficient in melanoma.', Pigment Cell and Melanoma Research (2014) [E3]
DOI 10.1111/pcmr.12292
Co-authors Vicki E Maltby
2014 Budden T, Bowden NA, 'Melanoma exhibits defective nucleotide excision repair of UVB-induced DNA photoproducts', Pigment Cell and Melanoma Research (2014) [E3]
DOI 10.1111/pcmr.12292
2014 Bolton KA, Holliday EG, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is a modifier of disease risk in endometrial cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Co-authors Liz Holliday, Kelly Kiejda, Rodney Scott
2014 Davey RJ, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'XPC expression is associated with BRAFV600E and NRASQ61R mutations and poor survival in melanoma.', ASMR Satellite scientific meeting proceedings (2014) [E3]
Co-authors Katie Ashton, Rodney Scott
2014 Murray HC, Maltby VE, Bowden NA, 'Nucleotide excision repair function in melanoma.', ASMR Satellite scientific meeting proceedings (2014) [E3]
2014 Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'The expression of the previously uncharacterised isoform, Bcl-2B is associated with increased survival in melanoma.', ASMR Satellite scientific meeting proceedings (2014) [E3]
Co-authors Katie Ashton, Pablo Moscato
2014 Budden T, Bowden NA, 'Melanoma displays reduced nucleotide excision repair in response to UVB-induced DNA damage', ASMR Scientific Satellite Meeting Proceedings (2014) [E3]
2014 Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen gene EIG121 is a potential modifier of endometrial cancer risk.', Asia-Pacific Journal of Clinical Oncology (2014) [E3]
DOI 10.1111/ajco.12335
Co-authors Liz Holliday, John Attia, Mark Mcevoy, Kelly Kiejda, Rodney Scott
2014 Bowden NA, 'Investigation of the nucleotide excision repair pathway for melanoma biomarkers', Cure Cancer Australia symposium proceedings (2014) [E3]
2013 Bolton KA, Ross J, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Role of Short Tandem Repeats in Disease and Evolutionary Mechanisms.', 34th Lorne Genome Conference Proceedings (2013) [E3]
Co-authors Liz Holliday, Kelly Kiejda, Rodney Scott
2013 Davey RJ, Ashton KA, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Nucleotide excision repair: biomarkers of UV-radiation and disease progression in melanoma.', HMRI Translational Cancer Research Conference (2013)
2013 Budden T, Scott RJ, Bowden NA, 'Altered nucleotide excision repair in melanoma in response to UVB-induced DNA damage.', HMRI Translational Cancer Research Conference (2013)
2013 Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Expression of the alternatively spliced variants of Bcl-2 in melanoma', HMRI Translational Cancer Research Conference (2013)
2013 Ashton KA, Davey RJ, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Investigation of UV radiation, clinical data and the transcriptome of diagnostic melanoma tissue.', HMRI Translational Cancer Research Conference (2013)
2013 Murray HC, Maltby VE, Bowden NA, 'Deficient expression of global genome nucleotide excision repair genes in melanoma cells following UVA irradiation.', HMRI Translational Cancer Research Conference (2013)
2013 Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden N, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in familial breast cancer.', Kathleen Cunningham Foundation Consortium for Research into Familial Aspects of Cancer 2013 Research and Practice Proceedings (2013) [E3]
Co-authors Rodney Scott, Michelle Wong-Brown, Kelly Kiejda
2013 Wong-Brown M, Avery-Kiejda K, Bowden N, Scott R, 'Prevalence of BRCA1 and BRCA2 germline mutations in triple-negative breast cancer', Programme (2013) [E3]
Citations Web of Science - 15
Co-authors Rodney Scott, Michelle Wong-Brown, Kelly Kiejda
2013 Bolton KA, Avery-Kiejda KA, Grice DM, Holliday EG, Bowden NA, Ross J, Scott RJ, 'STaRRRT: Our new resource for identifying candidates of genetic risk in breast and endometrial cancer.', Translational Cancer Research Conference Abstract booklet (2013) [E3]
Co-authors Kelly Kiejda, Liz Holliday, Rodney Scott
2013 Ashton KA, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Investigation of clinical parameters and altered transcriptome expression associated with UV radiation in melanoma.', Pigment Cell and Melanoma Research (2013)
DOI 10.1111/pcmr.12166
2013 Murray HC, Maltby VE, Bowden NA, 'Nucleotide Excision Repair of UVA-Induced DNA Damage: Function in Sunlight-Induced Melanoma.', Pigment Cell and Melanoma Research (2013)
DOI 10.1111/pcmr.12166
2013 Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Expression of the uncharacterised Bcl-2 isoform, Bcl-2ß, in melanoma.', Pigment Cell and Melanoma Research (2013)
DOI 10.1111/pcmr.12166
2013 Davey RJ, Ashton KA, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Investigation of the nucleotide excision repair pathway for biomarkers of UV-radiation and disease progression in melanoma.', Pigment Cell and Melanoma Research (2013)
DOI 10.1111/pcmr.12166
2013 Budden T, Scott RJ, Bowden NA, 'Possible Role for Nucleotide Excision Repair and UVB-induced DNA damage in Melanoma Development', Pigment Cell and Melanoma Research (2013)
DOI 10.1111/pcmr.12166
2012 Bowden NA, Ashton K, Vilian R, Braye S, Scott R, 'DNA repair transcripts: biomarkers of sun exposure and tumour aggression in melanoma', Abstract book (2012) [E3]
2012 Bolton KA, Ross J, Grice DM, Kiejda KA, Bowden NA, Holliday EG, Scott R, 'Potential role of short tandem repeats in disease processes', Abstracts. 6th Australian Health & Medical Research Congress (2012) [E3]
Co-authors Liz Holliday, Kelly Kiejda, Rodney Scott
2012 Bowden NA, Ashton KA, Vilain RE, Braye SG, Avery-Kiejda KA, Zhang XD, et al., 'Regulators of DNA repair do not respond to DNA damaging therapy but correlate with survival in melanoma.', Biomarker Discovery Conference Proceedings (2012)
2012 Bowden NA, 'Utilisation of personal CNV for diagnosis and treatment of cancer - A discussion of 2 cases in a clinical setting', Biomarker Discovery Conference Proceedings (2012)
2012 Wong M, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Human Genome Meeting (2012)
2012 Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Exploratory targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012 (2012) [E3]
Co-authors Michelle Wong-Brown, Kelly Kiejda, Rodney Scott
2012 Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Cancer Research (2012) [E3]
Co-authors Michelle Wong-Brown, Kelly Kiejda, Rodney Scott
2011 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research (2011) [E3]
DOI 10.1111/j.1755-148X.2011.00909.x
Co-authors Katie Ashton, Kelly Kiejda, Rodney Scott, Xu Zhang
2011 Johansson P, Wei JS, Chen Q, Bowden NA, Badgett TC, Song YK, et al., 'A genomic portrait of tumor progression using next-generation sequencing', American Association for Cancer Research (AACR) 102nd Annual Meeting. Innovation and Collaboration: The Path to Progress Proceedings (2011) [E3]
2011 Foster P, Li J, Wang W, Baines K, Bowden N, Hansbro P, et al., 'IL-27 underpins steroid resistant airway hyperresponsiveness via MyD88 dependent pathways', ALLERGY (2011) [E3]
Co-authors Ming Yang, Philip Hansbro, Peter Gibson
2010 Croft AJ, Kiejda KA, Bowden NA, Zhang X, Scott R, Hersey P, 'Expression profiling on apoptosis-related genes in cisplatin-treated human melanoma cell lines', 22nd Lorne Cancer Conference: Abstracts and Delegate Information (2010) [E3]
Co-authors Rodney Scott, Kelly Kiejda
2010 Wong-Brown M, Bowden NA, Kiejda KA, Scott R, 'BRIP1 and PALB2 mutation detection in Hunter-New England familial breast cancer cohort', 27th HUGO-IABCR Congress 2010. Genomics, Biology and Breast Cancer Treatment. Programme & Abstract Book (2010) [E3]
Co-authors Kelly Kiejda, Rodney Scott, Michelle Wong-Brown
2010 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts (2010) [E3]
DOI 10.1158/0008-5472.CAN-10-0161
Co-authors Kelly Kiejda, Xu Zhang, Rodney Scott, Katie Ashton
2010 Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book (2010) [E3]
Co-authors Kelly Kiejda, Rodney Scott, Katie Ashton, Xu Zhang
2010 Wong-Brown M, Bowden NA, Forbes JF, Braye SG, Scott R, 'Microsatellite instability (I) in breast tumours', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book (2010) [E3]
Co-authors Michelle Wong-Brown, John Forbes, Rodney Scott
2010 Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts (2010) [E3]
Co-authors Katie Ashton, Xu Zhang, Kelly Kiejda
2010 Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts (2010) [E3]
DOI 10.1158/0008-5472.CAN-10-0161
Co-authors Katie Ashton, Kelly Kiejda, Xu Zhang
2010 Vilain RE, Ashton KA, Bowden NA, Braye SG, Ashman LK, Scott RJ, 'Clinicopathological and gene expression profiling of advanced melanoma harbouring KIT and common kinase mutations', Melanoma 2010 Congress. Oral and Poster Abstracts (2010) [E3]
Co-authors Leonie Ashman, Katie Ashton
2009 Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference (2009) [E3]
Co-authors Rodney Scott, Chenchen Jiang, Xu Zhang, Kelly Kiejda
2009 Cox MB, Bowden NA, Scott R, Lechner-Scott J, 'Gene expression profiling in multiple sclerosis', AMATA 2009 (2009) [E3]
Co-authors Rodney Scott
2009 Evans T-J, Bowden NA, Talseth-Palmer B, Catchpoole D, Scott R, 'Copy number variation in childhood acute lmphoblastic leukaemia', AMATA 2009 (2009) [E3]
Co-authors Rodney Scott, Bente Talseth-Palmer
2009 Bowden NA, Ashton KA, Stibbard GJ, Cox MB, Baines KJ, Scott R, 'Predicting xeroderma pigmentosum complementation group by gene expression profiling', AMATA 2009 (2009) [E3]
Co-authors Katie Ashton, Rodney Scott, Katherine Baines
2009 Kairupan CF, Bowden NA, Ashton KA, Zhang XD, Hersey P, Scott R, 'Gene expression profiling in malignant melanoma', AMATA 2009 (2009) [E3]
Co-authors Katie Ashton, Rodney Scott, Xu Zhang
2008 Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008 (2008) [E3]
Co-authors Xu Zhang, Rodney Scott, Katie Ashton, Kelly Kiejda
2008 Bowden NA, Baines KJ, Cox MB, Scott R, 'Altered gene expression in nucleotide excision repair deficient fibroblasts after UV-light exposure', AACR Meeting Abstracts (2008) [E3]
Co-authors Rodney Scott, Katherine Baines
2008 Bowden NA, Baines KJ, Cox MB, Scott R, 'Response to uv-light exposure in fibroblasts with differential nucleotide excision repair capacity', ASMR XVII NSW Scientific Meeting: Programme and Abstracts (2008) [E3]
Co-authors Rodney Scott, Katherine Baines
2008 Bowden NA, Ashton KA, Baines KJ, Cox MB, Scott R, 'Altered gene expression after UV-light induced DNA damage', Conference on Translational Cancer Research: Abstracts (2008) [E3]
Co-authors Katie Ashton, Katherine Baines, Rodney Scott
2007 Baines KJ, Bowden NA, Scott R, Simpson JL, Gibson PG, 'Molecular analysis of neutrophils in asthma subtypes', Respirology (TSANZ Abstracts-Posters) (2007) [E3]
DOI 10.1111/j.1440-1843.2007.001050.x
Co-authors Jodie Simpson, Peter Gibson, Rodney Scott, Katherine Baines
2007 Cox M, Bowden NA, Moscato PA, Berretta RE, Scott R, 'Memetic algorithms as a new method to interpret gene expression profiles in multiple sclerosis', Multiple Sclerosis (Abstracts of the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in Multiple Sclerosis) (2007) [E3]
Citations Web of Science - 2
Co-authors Rodney Scott, Pablo Moscato, Regina Berretta
2007 Tooney PA, Scott R, Cairns MJ, Bowden NA, 'Altered gene expression in the superior temporial gyrus in schizophrenia', Schizophrenia Bulletin (Abstracts of the 11th International Congress on Schizophrenia Research) (2007) [E3]
Co-authors Paul Tooney, Murray Cairns, Rodney Scott
2006 Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Dysfunction of genes regulating membrane exocytosis in schizophrenia (Poster presentation)', Australian and New Zealand Journal of Psychiatry (Vol 40, noS2) (2006) [E3]
Co-authors Rodney Scott, Judith Weidenhofer, Paul Tooney
2005 Bowden NA, Weidenhofer JC, Scott R, Schall UA, Todd J, Michie PT, Tooney PA, 'Classification of schizophrenia using differential gene expression in peripheral blood lymphocytes', Human Genetics Society of Australasia (2005) [E3]
Co-authors Rodney Scott, Ulrich Schall, Paul Tooney, Juanita Todd, Pat Michie, Judith Weidenhofer
2004 Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Altered Expression of Brain Related Genes in Lymphocytes in Schizophrenia', American Journal of Medical Genetics (2004) [E3]
DOI 10.1002/ajmg.b.30101
Co-authors Judith Weidenhofer, Juanita Todd, Ulrich Schall, Rodney Scott, Paul Tooney
2004 Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Gene Profiling in the Amygdala in Schizophrenia', American Journal of Medical Genetics (2004) [E3]
Co-authors Judith Weidenhofer, Rodney Scott, Paul Tooney
2004 Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Differental Gene Expression in Peripheral Blood Lymphocytes in Schizophrenia', Proceedings of the Australian Neuroscience Society (2004) [E3]
Co-authors Rodney Scott, Ulrich Schall, Paul Tooney, Juanita Todd, Judith Weidenhofer
2004 Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Altered Gene Expression Profiles in the Amygdala in Schizophrenia', Proceedings of the Australian Neuroscience Society (2004) [E3]
Co-authors Paul Tooney, Judith Weidenhofer, Rodney Scott
2004 Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Distinct Gene Expression Profiles due to Age in Schizophrenia', Proceedings of the Australian Neuroscience Society (2004) [E3]
Co-authors Ulrich Schall, Rodney Scott, Judith Weidenhofer, Paul Tooney, Juanita Todd
Show 67 more conferences
Edit

Grants and Funding

Summary

Number of grants 34
Total funding $3,547,413

Click on a grant title below to expand the full details for that specific grant.


20161 grants / $55,000

Repurposing traditional chemotherapy to prime advanced melanoma for immune therapy.$55,000

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Doctor Nikola Bowden, Dr Andre van der Westhuizen
Scheme Health Investment Grant
Role Lead
Funding Start 2016
Funding Finish 2017
GNo G1500637
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

201511 grants / $1,570,083

Investigation of the DNA repair protein XPC in melanoma treatment resistance.$600,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Nikola Bowden
Scheme Career Development Fellowship
Role Lead
Funding Start 2015
Funding Finish 2017
GNo G1400706
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Expanding basic, clinical and functional genomic cancer research at Concord Campus$385,470

Funding body: Cancer Instititue NSW

Funding body Cancer Instititue NSW
Project Team

Nico van Zandwijk

Scheme Research Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor Marjorie Walker, Professor Xu Dong Zhang, Doctor Pradeep Tanwar, Doctor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Doctor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2015
Funding Finish 2018
GNo G1500825
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$124,938

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Research Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo G1500598
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Deep Learning of Complex Genomics Data for Effective Clinical Decisions.$60,000

Funding body: Cancer Instititue NSW

Funding body Cancer Instititue NSW
Scheme Big Data, Big Impact Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

Destroying kidney cells that evade current treatments$46,000

Funding body: Kidney Health Australia

Funding body Kidney Health Australia
Project Team Doctor Craig Gedye, Doctor Nikola Bowden, Professor Rodney Scott
Scheme Medical Research Project Grants
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1401048
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$25,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500953
Type Of Funding Internal
Category INTE
UON Y

Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$16,675

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Craig Gedye, Professor Rodney Scott, Doctor Nikola Bowden, Doctor Simon Keely, Doctor Kathryn Skelding
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500730
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Tour de Cure Travel Grant - AACR Conference, USA, April 2016 - Chloe Warren$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1600221
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Travel Grant - AACR Conference, USA, April 2016 - Moira Graves$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1600222
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Society for Melanoma Research Congress, San Fransisco USA, 18-22 November 2015$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Nikola Bowden
Scheme Travel Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501052
Type Of Funding Internal
Category INTE
UON Y

20141 grants / $60,000

Generating Actionable Knowledge from Complex Genomic Data for Personalised Clinical Decisions.$60,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team

Daniel Catchpoole

Scheme Big data, Big Impact Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

20132 grants / $360,198

Investigation of the nucleotide excision repair pathway for melanoma biomarkers. $199,782

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team Doctor Nikola Bowden
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2016
GNo G1200391
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Development of a chemotherapy response/resistance test for ovarian cancer$160,416

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2015
GNo G1300897
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20125 grants / $133,855

Research Equipment$54,355

Funding body: Hunter Melanoma Foundation

Funding body Hunter Melanoma Foundation
Project Team Doctor Nikola Bowden
Scheme Research Equipment Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1200936
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Development of a diagnostic genetic test for childhood skin cancer disorders$40,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden, Professor Rodney Scott
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200164
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Development of a diagnostic test for Xeroderma Pigmentosum , Cockayne’s Syndrome and Trichothiodystrophy$17,500

Funding body: The Marian & E. H. Flack Trust

Funding body The Marian & E. H. Flack Trust
Project Team Doctor Nikola Bowden
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1300524
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Emerging Research Leaders Program 2011$15,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikola Bowden
Scheme Emerging Research Leaders Program
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1101040
Type Of Funding Internal
Category INTE
UON Y

Rotary Club of Cardiff Melanoma Scholar Award$7,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1200831
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20112 grants / $590,811

Priority Research Centre for Cancer$555,811

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Professor John Forbes, Emeritus Professor Leonie Ashman, Doctor Nikola Bowden, Professor Gordon Burns, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Associate Professor Peter Stanwell, Doctor Rick Thorne, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2016
GNo G1101013
Type Of Funding Internal
Category INTE
UON Y

Nucleotide excision repair gene expression in melanoma$35,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden, Doctor Katie Ashton, Doctor Stephen Braye, Professor Rodney Scott, Dr Ricardo Vilain
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001057
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20102 grants / $91,975

Altered nucleotide excision repair in melanoma in response to cisplatin and UV-light irradiation$90,000

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team Doctor Nikola Bowden
Scheme Priority-driven Collaborative Cancer Research Scheme
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0190317
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

101st American Association of Cancer Research Annual Meeting, Convention Centre, Washington DC, USA, 17 - 21st April 2010$1,975

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Nikola Bowden
Scheme Travel Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G1000132
Type Of Funding Internal
Category INTE
UON Y

20093 grants / $518,921

Molecular mechanisms of UV-light induced skin malignancies$333,921

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Nikola Bowden
Scheme Early Career Fellowships
Role Lead
Funding Start 2009
Funding Finish 2014
GNo G0189304
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Genome wide SNP associated study of childhood acute lymphoblastic leukaemia$140,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Rodney Scott, Doctor Nikola Bowden, Doctor Bente Talseth-Palmer
Scheme Paediatric Oncology Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2010
GNo G0189790
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Gene expression profiling of Xeroderma pigmentosum$45,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Rodney Scott, Doctor Nikola Bowden, Doctor Katie Ashton
Scheme Postdoctoral Fellowship
Role Investigator
Funding Start 2009
Funding Finish 2010
GNo G0900194
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

20083 grants / $121,730

Gene expression profiling of xeroderma pigmentosum$100,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Rodney Scott, Doctor Nikola Bowden
Scheme Postdoctoral Fellowship
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188353
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Genome wide SNP association study of childhood acute lymphoblastic leukaemia$20,000

Funding body: Hunter Children`s Research Foundation

Funding body Hunter Children`s Research Foundation
Project Team Doctor Nikola Bowden, Professor Rodney Scott, Doctor Bente Talseth-Palmer
Scheme Paediatric Oncology Project Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188483
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Australian health & meidcal Research Congress, Brisbane Convention Centre, 16/11/2008 - 21/11/2008$1,730

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikola Bowden
Scheme Travel Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0189663
Type Of Funding Internal
Category INTE
UON Y

20073 grants / $33,000

Gene expression profiling of xeroderma pigmentosum$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden, Professor Rodney Scott
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187261
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Identification of a predictive approach to assigning to undefined xeroderma pigmentosum patients to subgroups using gene expression profiling$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187256
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Travel prize to attend: 4th Annual Illumina User Meeting (March '08) and American Association for Cancer Research (AACR) 99th Annual Meeting (April 12-16 '08)$3,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikola Bowden
Scheme PULSE Education Prize
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187298
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20061 grants / $11,840

Gene Expression Profiling of Xeroderma Pigmentosum$11,840

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Nikola Bowden
Scheme Early Career Researcher Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186964
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed4
Current3

Total current UON EFTSL

PhD2.3

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2013 PhD Nucleotide Excision Repair in Melanoma Development and Platinum Chemotherapy Resistance
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2013 PhD Expression of the Uncharacterised Isoform, BCL2ß, in Melanoma
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2012 PhD Examining Nucleotide Excision Repair Genes in Melanoma
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2016 PhD The Role of Short Tandem Repeats in Genetic Susceptibility to Breast and Endometrial Cancers
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2015 Masters Nucleotide Excision Repair of UVA-Induced DNA Damage: Regulation in Sunlight-Induced Melanoma
M Philosophy (Medical Genetic), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor
2014 PhD The Contribution of Genetic Susceptibility to Breast Cancer
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2013 PhD The Complex Genetics of Multiple Sclerosis
PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 48
United Kingdom 3
Canada 1
France 1
Poland 1
More...
Edit

News

DNA protein targeted in ovarian cancer

DNA protein targeted in ovarian cancer chemo test DNA protein targeted in ovarian cancer chemo test

February 25, 2015

University of Newcastle researcher Dr Nikola Bowden is investigating a DNA repair protein that is implicated in ovarian cancer tumours becoming resistant to chemotherapy, with hopes of eventually developing a prognostic test and more tailored treatments.

Dr Nikola Bowden

Position

Research Fellow
School of Medicine and Public Health
Faculty of Health and Medicine

Focus area

Medical Genetics

Contact Details

Email nikola.bowden@newcastle.edu.au
Phone (02) 40420277
Fax 02 40420031

Office

Room HMRI Level 3 West
Building HMRI
Location HMRI

,
Edit